For the Inventor, By the Inventor

Enter assignee name

Toronto, Canada

Trillium Therapeutics Inc.

USPTO Granted Patents = 29

% Expired Patents = 75.9

EPO Patents = 3

Forward Citations = 273

Loading Chart...

Loading Chart...

18 inventors (with patents filed for the assignee):

Reginald M Gorczynski (16 out of 18 patents)

David A Clark (10 out of 12 patents)

Abdelmalik Slassi (5 out of 59 patents)

4. Peter Dove (3 out of 7 patents)

5. Gary Levy (2 out of 5 patents)

6. Robert Adam Uger (2 out of 4 patents)

7. Penka Slavtcheva Slavova-Petrova (2 out of 2 patents)

8. Xinli Pang (2 out of 2 patents)

9. Phillip Mark Hogarth (2 out of 3 patents)

10. Mark Phillip Hogarth (2 out of 2 patents)

11. Gerard Peter Moloney (2 out of 2 patents)

12. Philip Marsden (2 out of 2 patents)

13. Geoffrey Allan Pietersz (2 out of 2 patents)

14. Bruce David Wines (1 out of 2 patents)

15. Karrie Ka Wai Wong (1 out of 1 patent)

Core Competencies:

CD47+ Disease Cells

SIRPalpha-Fc Fusions

Bromodomain Inhibitors

Fluorinated Compounds

CNS Disorders

Fc Receptor Modulation

Tumor Growth

Autoimmunity

OX-2 Antibodies

Immune Suppression

Transgenic Models

Therapeutic Agents

29 patents: Sort by Forward Citations

1. 10906954 - Treatment of CD47+ disease cells with SIRPα-Fc fusions (2021-02-02),

2. 10696670 - Fluorinated imidazo[4,5-C]quinoline derivatives as inhibitors of bromodomain containing proteins (2020-06-30),

3. 10604476 - Fluorinated amide derivatives and their uses as therapeutic agents (2020-03-31),

4. 10428030 - Heterocycle derivatives and their use for the treatment of CNS disorders (2019-10-01),

5. 10259809 - Fluorinated imidazo[4,5-C]quinoline derivatives as inhibitors of bromodomain containing proteins (2019-04-16),

6. 9969789 - Treatment of CD47+ disease cells with SIRP alpha-Fc fusions (2018-05-15),

7. 9441012 - Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors (2016-09-13),

8. 8729247 - Multimeric Fc receptor polypeptides (2014-05-20),

9. 8206897 - Assay for soluble CD200 (2012-06-26),

10. 8187598 - Methods of treating cancer by administering antibodies to CD200 (2012-05-29),

11. 7910770 - Fc receptor modulating compounds and compositions (2011-03-22),

12. 7902151 - Methods and compositions for modulating immunity (2011-03-08),

13. 7887798 - Methods of treating cancer by administering antibodies to CD200 (2011-02-15),

14. 7553811 - Methods and compositions for modulating immunity (2009-06-30),

15. 7452536 - Methods of treating cancer by administering antibodies to CD200 (2008-11-18),

Company Overview

Trillium Therapeutics Inc. is a biotechnology company based in Toronto, Canada, focused on developing innovative therapies for cancer treatment. The company specializes in harnessing the immune system to target and eliminate cancer cells, with a particular emphasis on its proprietary immune-oncology platform. Trillium's research aims to advance novel therapeutic approaches that enhance patient outcomes and address unmet medical needs in oncology, positioning it as a key player in the evolving landscape of cancer therapeutics.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

29 Patents

#51 in Toronto

#481 in Canada

#22,552 in the World

Toronto, Canada

Trillium Therapeutics Inc.

Forward Citations = 273

18 inventors:

Reginald M Gorczynski (16 out of 18 patents)

David A Clark (10 out of 12 patents)

Abdelmalik Slassi (5 out of 59 patents)

4. Peter Dove (3 out of 7 patents)

5. Gary Levy (2 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Trillium Therapeutics Inc.. Retrieved from https://idiyas.com/company/trillium-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…